Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RPC1063

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2017
Review
2017
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND AND PURPOSE Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac… Expand
  • figure 2
  • figure 1
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2015
Review
2015
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… Expand
  • figure 1
  • figure 2
Is this relevant?
2014
2014
OBJECTIVE: Evaluate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063 and its metabolites. BACKGROUND… Expand
Is this relevant?
2014
2014
Objective: Assess whether RPC1063 increases the corrected QT (QTc) interval compared to placebo (PBO). Background: RPC1063 is an… Expand
Is this relevant?
2013
2013
OBJECTIVE: To assess safety and tolerability of oral RPC1063 as single and multiple daily doses in healthy adults. BACKGROUND… Expand
Is this relevant?
2013
2013
OBJECTIVE: Identify metabolites of RPC1063 and determine their activity in vitro and in vivo. BACKGROUND: RPC1063 is a potent… Expand
Is this relevant?